Resolving Cancer and Fighting Cancer

Authors: Tamara Galvan Rachael Dyer Laura Phillips Debbie Villa Richard Russo

Published Date: 07-12-2017

Arizona State University-Tempe

School of Biology

KPC-K protein is of interest to integrally active chemists in the fight against cancer, especially because it contains proteins not found on any other biological cell and these proteins are sensitive to chemotherapy.

Drugs used for cancer treatment on this protein carry high toxicity even on normal tissues. In a study, TSRI researchers report the enzyme migration of the drug initiator and an analysis of how the KPC-K protein regulates this migration.

In the study, the researcher found that while the protein and chemotherapeutic drug effects are not coordinated, there is a level of interaction that both works in tandem to transport the chemotherapeutic drug into the cell.

How it works

Because of its non-coding RNA structure, kPC-K is difficult to study. To determine the effect of the drug initiator in the gut membrane and to understand how it affects the protein, the research team analyzed the protein biosynthesis and migration of the drug initiator (the enzyme that initiates activation) under laboratory conditions.

The study on the KPC-K protein biosynthesis and migration enabled researchers to take a closer look at the interactions involved in chemical reactions related to KPC-K. The study also revealed the intense physiologic pressures exerted by the protease as a result of the compressive property of the protein and the unknown effects of environmental interactions on the interaction between the protease and the drug initiator.

In a related work, researchers report the bimanual pathways involved in the transport of the therapeutic drug initiator and protease within and between tissues. This work highlights the fact that the final protein biosynthesis and migration are simultaneous, indicating a very complex movement of the drug initiator and the protease as the drug penetrates into the cell.

Other research on this protein has revealed that the protein is extremely active when it comes to the aggregation of cancer-related proteins (Hox genes). Thatâ€™s why researchers could focus on studying the perturbations in KPC-K protein dynamics while studying the Hox genes to gain insights into the basic physiological activity of these enzymes.

The team showed that the ephylactic effect of drugs is driven by a discontinuity in the internal helicical architecture of the protease (that is, the junction with the capillary) while at the same time drugs stimulate an ephylactic response by the protease to stimulate protease secretion and infusion. The drug initiator activates a complex interaction between ephylactic and secondary transport mediated by the protease while simultaneously stimulating ephylactic propagation by the protease, the researchers concluded.

Collaborators include Brenda Wu (physician and science journalist; Stanford Medical School), Emilio Sixti (Molecular Nutrition and Food Sciences at Rockefeller University), Santina Sandral (Radiomics and Epigenetics graduate student in Pablo Fioravantiâ€™s laboratory), Rana Ahmed (Professor of Chemistry in Pablo Fioravantiâ€™s lab) and Pablo Fioravanti (Molecular Genetics and Epigenetics at TSRI).

Funding for this research came from the U.S. National Institutes of Health and the European Research Council.

For more information about this work, please contact Laura Garci Alonso (L.G.I.A. at lgariaber@rti.org.es).

The authors declare no financial or other conflicts of interest.

A request for permission to publish this paper was made by Andrea Hidalgo and Olga W. Hidalgo.

A Brown Teddy Bear Sitting On Top Of A Grass Covered Field